Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Growth 2026-2032
The global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market size is predicted to grow from US$ 17.61 million in 2025 to US$ 69.20 million in 2032; it is expected to grow at a CAGR of 18.2% from 2026 to 2032.
Ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals are high purity small molecule precursor materials used to manufacture prostate specific membrane antigen targeted alpha radiotherapeutics. The research scope focuses on non radioactive ligand compounds, clinical grade precursors and GMP grade precursors that can be chelated and labeled with actinium 225 for radiopharmaceutical production. These products are generally built from a PSMA binding motif, a molecular linker, a metal chelator and a radiolabeling ready functional structure. Main product forms include lyophilized precursor powder, standardized vial based precursor materials, custom synthesized intermediates and clinical batch precursors. Their production process involves multistep organic synthesis, peptide or peptidomimetic structure construction, chelator conjugation, impurity profiling, preparative purification, low bioburden control, stability testing and GMP documentation. Key specifications usually include chemical purity, individual impurity limits, residual solvents, water content, endotoxin, metal impurities, radiolabeling yield, radiochemical purity, identity confirmation and batch to batch consistency. The core function of these precursors is to provide nuclear medicine developers, radiopharmaceutical CDMOs, clinical research institutions and hospital nuclear medicine centers with reproducible and regulatory supportable starting materials for PSMA targeted alpha therapy manufacturing. Main applications are concentrated in clinical development and early commercial validation of targeted alpha radiopharmaceuticals for PSMA positive tumors, especially metastatic castration resistant prostate cancer. In 2025, the global average gross margin of ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals is estimated at about 55%.
Ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals represent a highly specialized upstream material segment within the radiopharmaceutical value chain. The upstream side includes actinium 225 radioisotope supply, chelators, protected amino acids, peptide synthesis inputs, GMP grade solvents and high purity reagents. The midstream layer covers PSMA ligand design, precursor synthesis, purification, analytical characterization, process scale up and clinical batch preparation. The downstream side consists of radiopharmaceutical developers, nuclear medicine CDMOs, hospital nuclear medicine centers and oncology clinical research networks. This product category should not be interpreted as a general research reagent or as a final therapeutic radiopharmaceutical. Its commercial value is concentrated in regulatory grade quality control, labeling compatibility with Ac 225, impurity management, stability data and the ability to support repeatable clinical manufacturing. Since Ac 225 PSMA targeted alpha therapy is still moving through clinical development, demand is currently driven mainly by GMP validation batches, clinical trial supply, custom synthesis and equivalent in house consumption by drug developers, rather than by full commercial scale drug manufacturing.
The competitive landscape remains narrow and concentrated. Only a small number of global suppliers can be reasonably identified as actual manufacturers of PSMA radioligand precursors with relevant production evidence, while a broader group of pharmaceutical companies and nuclear medicine platforms should be treated as pipeline owners rather than precursor manufacturers. Europe and the United States are the most important supply regions, supported by established radiopharmaceutical chemistry, GMP manufacturing know how and clinical trial infrastructure. China, Japan, South Korea and India have growing capabilities in peptide synthesis, pharmaceutical CDMO services and nuclear medicine development, but public evidence for stable production of Ac 225 compatible PSMA ligand precursors remains limited. Competition is less about bulk capacity and more about GMP readiness, analytical documentation, batch reproducibility, customer project linkage and intellectual property around ligand and chelator structures. Recent mergers and acquisitions in the radiopharmaceutical sector have strengthened the strategic importance of upstream precursor control and are gradually increasing clinical batch demand.
The policy environment is generally supportive, as major healthcare markets continue to encourage nuclear medicine, targeted radiotherapy, medical isotope supply and precision oncology infrastructure. However, the industry is still constrained by limited Ac 225 availability, radiopharmaceutical manufacturing licenses, transport restrictions, clinical development timelines and regulatory uncertainty. Future growth will mainly come from three sources: the advancement of PSMA targeted alpha therapy pipelines into later clinical stages, the gradual expansion of isotope supply that enables early commercial validation, and the development of next generation PSMA ligands with improved chelation stability, tumor retention and manufacturability. The market should therefore be viewed as a small scale but high value emerging segment. In the near term, it should not be benchmarked against the broader radiopharmaceutical drug market, but over the medium to long term it has strong strategic value because precursor quality, process reliability and supply security can directly affect clinical progress and commercialization readiness.
LP Information, Inc. (LPI) ' newest research report, the ?Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Forecast? looks at past sales and reviews total world Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals sales in 2025, providing a comprehensive analysis by region and market sector of projected Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals sales for 2026 through 2032. With Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals industry.
This Insight Report provides a comprehensive analysis of the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals and breaks down the forecast by Form, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals.
This report presents a comprehensive overview, market shares, and growth opportunities of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market by product type, application, key manufacturers and key regions and countries.
Segmentation by Form:
What is the 10-year outlook for the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
What factors are driving Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market opportunities vary by end market size?
How does Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals break out by Form, by Application?
Ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals are high purity small molecule precursor materials used to manufacture prostate specific membrane antigen targeted alpha radiotherapeutics. The research scope focuses on non radioactive ligand compounds, clinical grade precursors and GMP grade precursors that can be chelated and labeled with actinium 225 for radiopharmaceutical production. These products are generally built from a PSMA binding motif, a molecular linker, a metal chelator and a radiolabeling ready functional structure. Main product forms include lyophilized precursor powder, standardized vial based precursor materials, custom synthesized intermediates and clinical batch precursors. Their production process involves multistep organic synthesis, peptide or peptidomimetic structure construction, chelator conjugation, impurity profiling, preparative purification, low bioburden control, stability testing and GMP documentation. Key specifications usually include chemical purity, individual impurity limits, residual solvents, water content, endotoxin, metal impurities, radiolabeling yield, radiochemical purity, identity confirmation and batch to batch consistency. The core function of these precursors is to provide nuclear medicine developers, radiopharmaceutical CDMOs, clinical research institutions and hospital nuclear medicine centers with reproducible and regulatory supportable starting materials for PSMA targeted alpha therapy manufacturing. Main applications are concentrated in clinical development and early commercial validation of targeted alpha radiopharmaceuticals for PSMA positive tumors, especially metastatic castration resistant prostate cancer. In 2025, the global average gross margin of ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals is estimated at about 55%.
Ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals represent a highly specialized upstream material segment within the radiopharmaceutical value chain. The upstream side includes actinium 225 radioisotope supply, chelators, protected amino acids, peptide synthesis inputs, GMP grade solvents and high purity reagents. The midstream layer covers PSMA ligand design, precursor synthesis, purification, analytical characterization, process scale up and clinical batch preparation. The downstream side consists of radiopharmaceutical developers, nuclear medicine CDMOs, hospital nuclear medicine centers and oncology clinical research networks. This product category should not be interpreted as a general research reagent or as a final therapeutic radiopharmaceutical. Its commercial value is concentrated in regulatory grade quality control, labeling compatibility with Ac 225, impurity management, stability data and the ability to support repeatable clinical manufacturing. Since Ac 225 PSMA targeted alpha therapy is still moving through clinical development, demand is currently driven mainly by GMP validation batches, clinical trial supply, custom synthesis and equivalent in house consumption by drug developers, rather than by full commercial scale drug manufacturing.
The competitive landscape remains narrow and concentrated. Only a small number of global suppliers can be reasonably identified as actual manufacturers of PSMA radioligand precursors with relevant production evidence, while a broader group of pharmaceutical companies and nuclear medicine platforms should be treated as pipeline owners rather than precursor manufacturers. Europe and the United States are the most important supply regions, supported by established radiopharmaceutical chemistry, GMP manufacturing know how and clinical trial infrastructure. China, Japan, South Korea and India have growing capabilities in peptide synthesis, pharmaceutical CDMO services and nuclear medicine development, but public evidence for stable production of Ac 225 compatible PSMA ligand precursors remains limited. Competition is less about bulk capacity and more about GMP readiness, analytical documentation, batch reproducibility, customer project linkage and intellectual property around ligand and chelator structures. Recent mergers and acquisitions in the radiopharmaceutical sector have strengthened the strategic importance of upstream precursor control and are gradually increasing clinical batch demand.
The policy environment is generally supportive, as major healthcare markets continue to encourage nuclear medicine, targeted radiotherapy, medical isotope supply and precision oncology infrastructure. However, the industry is still constrained by limited Ac 225 availability, radiopharmaceutical manufacturing licenses, transport restrictions, clinical development timelines and regulatory uncertainty. Future growth will mainly come from three sources: the advancement of PSMA targeted alpha therapy pipelines into later clinical stages, the gradual expansion of isotope supply that enables early commercial validation, and the development of next generation PSMA ligands with improved chelation stability, tumor retention and manufacturability. The market should therefore be viewed as a small scale but high value emerging segment. In the near term, it should not be benchmarked against the broader radiopharmaceutical drug market, but over the medium to long term it has strong strategic value because precursor quality, process reliability and supply security can directly affect clinical progress and commercialization readiness.
LP Information, Inc. (LPI) ' newest research report, the ?Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Forecast? looks at past sales and reviews total world Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals sales in 2025, providing a comprehensive analysis by region and market sector of projected Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals sales for 2026 through 2032. With Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals industry.
This Insight Report provides a comprehensive analysis of the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals and breaks down the forecast by Form, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals.
This report presents a comprehensive overview, market shares, and growth opportunities of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market by product type, application, key manufacturers and key regions and countries.
Segmentation by Form:
- Lyophilized Precursor Powder
- Solution Form Precursor
- Others
- Research Grade
- Analytical Grade
- Clinical Grade
- GMP Grade
- Others
- PSMA 617 Based Precursors
- PSMA I&T Based Precursors
- Radiohybrid PSMA Precursors
- Bispecific or Multivalent PSMA Precursors
- Next Generation PSMA Precursors
- Others
- DOTA Based Chelator Precursors
- DOTAGA Based Chelator Precursors
- TCMC Based Chelator Precursors
- Macropa Based Chelator Precursors
- Others
- argeted Alpha Therapy
- Radiolabeling Process Development
- Clinical Trial Drug Manufacturing
- Quality Control and Reference Use
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- ABX Advanced Biochemical Compounds GmbH
- Radnostix, Inc.
- JPT Peptide Technologies GmbH
- SCINTOMICS Molecular, Applied Theranostics Technologies GmbH
What is the 10-year outlook for the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
What factors are driving Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market opportunities vary by end market size?
How does Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals break out by Form, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals by Country/Region, 2021, 2025 & 2032
2.2 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Segment by Form
2.2.1 Lyophilized Precursor Powder
2.2.2 Solution Form Precursor
2.2.3 Others
2.2.4 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form
2.2.4.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
2.2.4.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue and Market Share by Form (2021-2026)
2.2.4.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Form (2021-2026)
2.3 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Segment by Quality Grade
2.3.1 Research Grade
2.3.2 Analytical Grade
2.3.3 Clinical Grade
2.3.4 GMP Grade
2.3.5 Others
2.3.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Quality Grade
2.3.6.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Quality Grade (2021-2026)
2.3.6.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue and Market Share by Quality Grade (2021-2026)
2.3.6.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Quality Grade (2021-2026)
2.4 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Segment by Ligand Platform
2.4.1 PSMA 617 Based Precursors
2.4.2 PSMA I&T Based Precursors
2.4.3 Radiohybrid PSMA Precursors
2.4.4 Bispecific or Multivalent PSMA Precursors
2.4.5 Next Generation PSMA Precursors
2.4.6 Others
2.4.7 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Ligand Platform
2.4.7.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Ligand Platform (2021-2026)
2.4.7.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue and Market Share by Ligand Platform (2021-2026)
2.4.7.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Ligand Platform (2021-2026)
2.5 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Segment by Chelator System
2.5.1 DOTA Based Chelator Precursors
2.5.2 DOTAGA Based Chelator Precursors
2.5.3 TCMC Based Chelator Precursors
2.5.4 Macropa Based Chelator Precursors
2.5.5 Others
2.5.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Chelator System
2.5.6.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Chelator System (2021-2026)
2.5.6.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue and Market Share by Chelator System (2021-2026)
2.5.6.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Chelator System (2021-2026)
2.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Segment by Application
2.6.1 argeted Alpha Therapy
2.6.2 Radiolabeling Process Development
2.6.3 Clinical Trial Drug Manufacturing
2.6.4 Quality Control and Reference Use
2.6.5 Others
2.6.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application
2.6.6.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Market Share by Application (2021-2026)
2.6.6.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue and Market Share by Application (2021-2026)
2.6.6.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Breakdown Data by Company
3.1.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales by Company (2021-2026)
3.1.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Company (2021-2026)
3.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue by Company (2021-2026)
3.2.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Company (2021-2026)
3.2.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Company (2021-2026)
3.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Company
3.4 Key Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Location Distribution
3.4.2 Players Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LIGAND PRECURSORS FOR AC-225-LABELED PSMA TARGETED RADIOPHARMACEUTICALS BY GEOGRAPHIC REGION
4.1 World Historic Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size by Geographic Region (2021-2026)
4.1.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size by Country/Region (2021-2026)
4.2.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales by Country/Region (2021-2026)
4.2.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue by Country/Region (2021-2026)
4.3 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Growth
4.4 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Growth
4.5 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Growth
4.6 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Growth
5 AMERICAS
5.1 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country
5.1.1 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026)
5.1.2 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country (2021-2026)
5.2 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026)
5.3 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Region
6.1.1 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Region (2021-2026)
6.1.2 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Region (2021-2026)
6.2 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026)
6.3 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals by Country
7.1.1 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026)
7.1.2 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country (2021-2026)
7.2 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026)
7.3 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals by Country
8.1.1 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026)
8.1.2 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country (2021-2026)
8.2 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026)
8.3 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
10.3 Manufacturing Process Analysis of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
10.4 Industry Chain Structure of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Distributors
11.3 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Customer
12 WORLD FORECAST REVIEW FOR LIGAND PRECURSORS FOR AC-225-LABELED PSMA TARGETED RADIOPHARMACEUTICALS BY GEOGRAPHIC REGION
12.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Forecast by Region
12.1.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Forecast by Region (2027-2032)
12.1.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Forecast by Form (2027-2032)
12.7 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ABX Advanced Biochemical Compounds GmbH
13.1.1 ABX Advanced Biochemical Compounds GmbH Company Information
13.1.2 ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
13.1.3 ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ABX Advanced Biochemical Compounds GmbH Main Business Overview
13.1.5 ABX Advanced Biochemical Compounds GmbH Latest Developments
13.2 Radnostix, Inc.
13.2.1 Radnostix, Inc. Company Information
13.2.2 Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
13.2.3 Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Radnostix, Inc. Main Business Overview
13.2.5 Radnostix, Inc. Latest Developments
13.3 JPT Peptide Technologies GmbH
13.3.1 JPT Peptide Technologies GmbH Company Information
13.3.2 JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
13.3.3 JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 JPT Peptide Technologies GmbH Main Business Overview
13.3.5 JPT Peptide Technologies GmbH Latest Developments
13.4 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH
13.4.1 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Company Information
13.4.2 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
13.4.3 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Main Business Overview
13.4.5 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals by Country/Region, 2021, 2025 & 2032
2.2 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Segment by Form
2.2.1 Lyophilized Precursor Powder
2.2.2 Solution Form Precursor
2.2.3 Others
2.2.4 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form
2.2.4.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
2.2.4.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue and Market Share by Form (2021-2026)
2.2.4.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Form (2021-2026)
2.3 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Segment by Quality Grade
2.3.1 Research Grade
2.3.2 Analytical Grade
2.3.3 Clinical Grade
2.3.4 GMP Grade
2.3.5 Others
2.3.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Quality Grade
2.3.6.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Quality Grade (2021-2026)
2.3.6.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue and Market Share by Quality Grade (2021-2026)
2.3.6.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Quality Grade (2021-2026)
2.4 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Segment by Ligand Platform
2.4.1 PSMA 617 Based Precursors
2.4.2 PSMA I&T Based Precursors
2.4.3 Radiohybrid PSMA Precursors
2.4.4 Bispecific or Multivalent PSMA Precursors
2.4.5 Next Generation PSMA Precursors
2.4.6 Others
2.4.7 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Ligand Platform
2.4.7.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Ligand Platform (2021-2026)
2.4.7.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue and Market Share by Ligand Platform (2021-2026)
2.4.7.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Ligand Platform (2021-2026)
2.5 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Segment by Chelator System
2.5.1 DOTA Based Chelator Precursors
2.5.2 DOTAGA Based Chelator Precursors
2.5.3 TCMC Based Chelator Precursors
2.5.4 Macropa Based Chelator Precursors
2.5.5 Others
2.5.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Chelator System
2.5.6.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Chelator System (2021-2026)
2.5.6.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue and Market Share by Chelator System (2021-2026)
2.5.6.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Chelator System (2021-2026)
2.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Segment by Application
2.6.1 argeted Alpha Therapy
2.6.2 Radiolabeling Process Development
2.6.3 Clinical Trial Drug Manufacturing
2.6.4 Quality Control and Reference Use
2.6.5 Others
2.6.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application
2.6.6.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Market Share by Application (2021-2026)
2.6.6.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue and Market Share by Application (2021-2026)
2.6.6.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Breakdown Data by Company
3.1.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales by Company (2021-2026)
3.1.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Company (2021-2026)
3.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue by Company (2021-2026)
3.2.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Company (2021-2026)
3.2.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Company (2021-2026)
3.3 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Company
3.4 Key Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Location Distribution
3.4.2 Players Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LIGAND PRECURSORS FOR AC-225-LABELED PSMA TARGETED RADIOPHARMACEUTICALS BY GEOGRAPHIC REGION
4.1 World Historic Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size by Geographic Region (2021-2026)
4.1.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size by Country/Region (2021-2026)
4.2.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales by Country/Region (2021-2026)
4.2.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue by Country/Region (2021-2026)
4.3 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Growth
4.4 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Growth
4.5 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Growth
4.6 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Growth
5 AMERICAS
5.1 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country
5.1.1 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026)
5.1.2 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country (2021-2026)
5.2 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026)
5.3 Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Region
6.1.1 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Region (2021-2026)
6.1.2 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Region (2021-2026)
6.2 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026)
6.3 APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals by Country
7.1.1 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026)
7.1.2 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country (2021-2026)
7.2 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026)
7.3 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals by Country
8.1.1 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026)
8.1.2 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country (2021-2026)
8.2 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026)
8.3 Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
10.3 Manufacturing Process Analysis of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
10.4 Industry Chain Structure of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Distributors
11.3 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Customer
12 WORLD FORECAST REVIEW FOR LIGAND PRECURSORS FOR AC-225-LABELED PSMA TARGETED RADIOPHARMACEUTICALS BY GEOGRAPHIC REGION
12.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Forecast by Region
12.1.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Forecast by Region (2027-2032)
12.1.2 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Forecast by Form (2027-2032)
12.7 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ABX Advanced Biochemical Compounds GmbH
13.1.1 ABX Advanced Biochemical Compounds GmbH Company Information
13.1.2 ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
13.1.3 ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ABX Advanced Biochemical Compounds GmbH Main Business Overview
13.1.5 ABX Advanced Biochemical Compounds GmbH Latest Developments
13.2 Radnostix, Inc.
13.2.1 Radnostix, Inc. Company Information
13.2.2 Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
13.2.3 Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Radnostix, Inc. Main Business Overview
13.2.5 Radnostix, Inc. Latest Developments
13.3 JPT Peptide Technologies GmbH
13.3.1 JPT Peptide Technologies GmbH Company Information
13.3.2 JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
13.3.3 JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 JPT Peptide Technologies GmbH Main Business Overview
13.3.5 JPT Peptide Technologies GmbH Latest Developments
13.4 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH
13.4.1 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Company Information
13.4.2 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
13.4.3 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Main Business Overview
13.4.5 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Lyophilized Precursor Powder
Table 4. Major Players of Solution Form Precursor
Table 5. Major Players of Others
Table 6. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026) & (kg)
Table 7. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
Table 8. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Form (2021-2026) & ($ million)
Table 9. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Form (2021-2026)
Table 10. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Form (2021-2026) & (US$/kg)
Table 11. Major Players of Research Grade
Table 12. Major Players of Analytical Grade
Table 13. Major Players of Clinical Grade
Table 14. Major Players of GMP Grade
Table 15. Major Players of Others
Table 16. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Quality Grade (2021-2026) & (kg)
Table 17. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Quality Grade (2021-2026)
Table 18. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Quality Grade (2021-2026) & ($ million)
Table 19. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Quality Grade (2021-2026)
Table 20. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Quality Grade (2021-2026) & (US$/kg)
Table 21. Major Players of PSMA 617 Based Precursors
Table 22. Major Players of PSMA I&T Based Precursors
Table 23. Major Players of Radiohybrid PSMA Precursors
Table 24. Major Players of Bispecific or Multivalent PSMA Precursors
Table 25. Major Players of Next Generation PSMA Precursors
Table 26. Major Players of Others
Table 27. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Ligand Platform (2021-2026) & (kg)
Table 28. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Ligand Platform (2021-2026)
Table 29. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Ligand Platform (2021-2026) & ($ million)
Table 30. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Ligand Platform (2021-2026)
Table 31. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Ligand Platform (2021-2026) & (US$/kg)
Table 32. Major Players of DOTA Based Chelator Precursors
Table 33. Major Players of DOTAGA Based Chelator Precursors
Table 34. Major Players of TCMC Based Chelator Precursors
Table 35. Major Players of Macropa Based Chelator Precursors
Table 36. Major Players of Others
Table 37. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Chelator System (2021-2026) & (kg)
Table 38. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Chelator System (2021-2026)
Table 39. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Chelator System (2021-2026) & ($ million)
Table 40. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Chelator System (2021-2026)
Table 41. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Chelator System (2021-2026) & (US$/kg)
Table 42. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale by Application (2021-2026) & (kg)
Table 43. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Market Share by Application (2021-2026)
Table 44. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Application (2021-2026) & ($ million)
Table 45. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Application (2021-2026)
Table 46. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Application (2021-2026) & (US$/kg)
Table 47. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Company (2021-2026) & (kg)
Table 48. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Company (2021-2026)
Table 49. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Company (2021-2026) & ($ millions)
Table 50. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Company (2021-2026)
Table 51. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Company (2021-2026) & (US$/kg)
Table 52. Key Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Producing Area Distribution and Sales Area
Table 53. Players Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Products Offered
Table 54. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 55. New Products and Potential Entrants
Table 56. Market M&A Activity & Strategy
Table 57. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Geographic Region (2021-2026) & (kg)
Table 58. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share Geographic Region (2021-2026)
Table 59. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Geographic Region (2021-2026) & ($ millions)
Table 60. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Geographic Region (2021-2026)
Table 61. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country/Region (2021-2026) & (kg)
Table 62. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country/Region (2021-2026)
Table 63. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country/Region (2021-2026) & ($ millions)
Table 64. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Country/Region (2021-2026)
Table 65. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026) & (kg)
Table 66. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country (2021-2026)
Table 67. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country (2021-2026) & ($ millions)
Table 68. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026) & (kg)
Table 69. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026) & (kg)
Table 70. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Region (2021-2026) & (kg)
Table 71. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Region (2021-2026)
Table 72. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Region (2021-2026) & ($ millions)
Table 73. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026) & (kg)
Table 74. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026) & (kg)
Table 75. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026) & (kg)
Table 76. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country (2021-2026) & ($ millions)
Table 77. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026) & (kg)
Table 78. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026) & (kg)
Table 79. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026) & (kg)
Table 80. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Table 81. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026) & (kg)
Table 82. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026) & (kg)
Table 83. Key Market Drivers & Growth Opportunities of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Table 84. Key Market Challenges & Risks of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Table 85. Key Industry Trends of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Table 86. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Raw Material
Table 87. Key Suppliers of Raw Materials
Table 88. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Distributors List
Table 89. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Customer List
Table 90. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Region (2027-2032) & (kg)
Table 91. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Forecast by Region (2027-2032) & ($ millions)
Table 92. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (kg)
Table 93. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 94. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Region (2027-2032) & (kg)
Table 95. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 96. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (kg)
Table 97. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Forecast by Country (2027-2032) & ($ millions)
Table 98. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (kg)
Table 99. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Forecast by Country (2027-2032) & ($ millions)
Table 100. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Form (2027-2032) & (kg)
Table 101. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Forecast by Form (2027-2032) & ($ millions)
Table 102. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Application (2027-2032) & (kg)
Table 103. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Forecast by Application (2027-2032) & ($ millions)
Table 104. ABX Advanced Biochemical Compounds GmbH Basic Information, Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 105. ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
Table 106. ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 107. ABX Advanced Biochemical Compounds GmbH Main Business
Table 108. ABX Advanced Biochemical Compounds GmbH Latest Developments
Table 109. Radnostix, Inc. Basic Information, Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 110. Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
Table 111. Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 112. Radnostix, Inc. Main Business
Table 113. Radnostix, Inc. Latest Developments
Table 114. JPT Peptide Technologies GmbH Basic Information, Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 115. JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
Table 116. JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 117. JPT Peptide Technologies GmbH Main Business
Table 118. JPT Peptide Technologies GmbH Latest Developments
Table 119. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Basic Information, Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 120. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
Table 121. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 122. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Main Business
Table 123. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Latest Developments
Table 1. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Lyophilized Precursor Powder
Table 4. Major Players of Solution Form Precursor
Table 5. Major Players of Others
Table 6. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026) & (kg)
Table 7. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
Table 8. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Form (2021-2026) & ($ million)
Table 9. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Form (2021-2026)
Table 10. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Form (2021-2026) & (US$/kg)
Table 11. Major Players of Research Grade
Table 12. Major Players of Analytical Grade
Table 13. Major Players of Clinical Grade
Table 14. Major Players of GMP Grade
Table 15. Major Players of Others
Table 16. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Quality Grade (2021-2026) & (kg)
Table 17. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Quality Grade (2021-2026)
Table 18. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Quality Grade (2021-2026) & ($ million)
Table 19. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Quality Grade (2021-2026)
Table 20. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Quality Grade (2021-2026) & (US$/kg)
Table 21. Major Players of PSMA 617 Based Precursors
Table 22. Major Players of PSMA I&T Based Precursors
Table 23. Major Players of Radiohybrid PSMA Precursors
Table 24. Major Players of Bispecific or Multivalent PSMA Precursors
Table 25. Major Players of Next Generation PSMA Precursors
Table 26. Major Players of Others
Table 27. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Ligand Platform (2021-2026) & (kg)
Table 28. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Ligand Platform (2021-2026)
Table 29. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Ligand Platform (2021-2026) & ($ million)
Table 30. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Ligand Platform (2021-2026)
Table 31. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Ligand Platform (2021-2026) & (US$/kg)
Table 32. Major Players of DOTA Based Chelator Precursors
Table 33. Major Players of DOTAGA Based Chelator Precursors
Table 34. Major Players of TCMC Based Chelator Precursors
Table 35. Major Players of Macropa Based Chelator Precursors
Table 36. Major Players of Others
Table 37. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Chelator System (2021-2026) & (kg)
Table 38. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Chelator System (2021-2026)
Table 39. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Chelator System (2021-2026) & ($ million)
Table 40. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Chelator System (2021-2026)
Table 41. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Chelator System (2021-2026) & (US$/kg)
Table 42. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale by Application (2021-2026) & (kg)
Table 43. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Market Share by Application (2021-2026)
Table 44. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Application (2021-2026) & ($ million)
Table 45. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Application (2021-2026)
Table 46. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Application (2021-2026) & (US$/kg)
Table 47. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Company (2021-2026) & (kg)
Table 48. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Company (2021-2026)
Table 49. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Company (2021-2026) & ($ millions)
Table 50. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Company (2021-2026)
Table 51. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Price by Company (2021-2026) & (US$/kg)
Table 52. Key Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Producing Area Distribution and Sales Area
Table 53. Players Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Products Offered
Table 54. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 55. New Products and Potential Entrants
Table 56. Market M&A Activity & Strategy
Table 57. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Geographic Region (2021-2026) & (kg)
Table 58. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share Geographic Region (2021-2026)
Table 59. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Geographic Region (2021-2026) & ($ millions)
Table 60. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Geographic Region (2021-2026)
Table 61. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country/Region (2021-2026) & (kg)
Table 62. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country/Region (2021-2026)
Table 63. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country/Region (2021-2026) & ($ millions)
Table 64. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Country/Region (2021-2026)
Table 65. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026) & (kg)
Table 66. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country (2021-2026)
Table 67. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country (2021-2026) & ($ millions)
Table 68. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026) & (kg)
Table 69. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026) & (kg)
Table 70. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Region (2021-2026) & (kg)
Table 71. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Region (2021-2026)
Table 72. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Region (2021-2026) & ($ millions)
Table 73. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026) & (kg)
Table 74. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026) & (kg)
Table 75. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026) & (kg)
Table 76. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Country (2021-2026) & ($ millions)
Table 77. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026) & (kg)
Table 78. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026) & (kg)
Table 79. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Country (2021-2026) & (kg)
Table 80. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Table 81. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Form (2021-2026) & (kg)
Table 82. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Application (2021-2026) & (kg)
Table 83. Key Market Drivers & Growth Opportunities of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Table 84. Key Market Challenges & Risks of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Table 85. Key Industry Trends of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Table 86. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Raw Material
Table 87. Key Suppliers of Raw Materials
Table 88. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Distributors List
Table 89. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Customer List
Table 90. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Region (2027-2032) & (kg)
Table 91. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Forecast by Region (2027-2032) & ($ millions)
Table 92. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (kg)
Table 93. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 94. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Region (2027-2032) & (kg)
Table 95. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 96. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (kg)
Table 97. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Forecast by Country (2027-2032) & ($ millions)
Table 98. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (kg)
Table 99. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Forecast by Country (2027-2032) & ($ millions)
Table 100. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Form (2027-2032) & (kg)
Table 101. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Forecast by Form (2027-2032) & ($ millions)
Table 102. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Forecast by Application (2027-2032) & (kg)
Table 103. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Forecast by Application (2027-2032) & ($ millions)
Table 104. ABX Advanced Biochemical Compounds GmbH Basic Information, Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 105. ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
Table 106. ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 107. ABX Advanced Biochemical Compounds GmbH Main Business
Table 108. ABX Advanced Biochemical Compounds GmbH Latest Developments
Table 109. Radnostix, Inc. Basic Information, Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 110. Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
Table 111. Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 112. Radnostix, Inc. Main Business
Table 113. Radnostix, Inc. Latest Developments
Table 114. JPT Peptide Technologies GmbH Basic Information, Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 115. JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
Table 116. JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 117. JPT Peptide Technologies GmbH Main Business
Table 118. JPT Peptide Technologies GmbH Latest Developments
Table 119. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Basic Information, Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 120. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product Portfolios and Specifications
Table 121. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 122. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Main Business
Table 123. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Latest Developments
LIST OF FIGURES
Figure 1. Picture of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Figure 2. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Growth Rate 2021-2032 (kg)
Figure 7. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country/Region (2025)
Figure 10. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Lyophilized Precursor Powder
Figure 12. Product Picture of Solution Form Precursor
Figure 13. Product Picture of Others
Figure 14. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form in 2026
Figure 15. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Form (2021-2026)
Figure 16. Product Picture of Research Grade
Figure 17. Product Picture of Analytical Grade
Figure 18. Product Picture of Clinical Grade
Figure 19. Product Picture of GMP Grade
Figure 20. Product Picture of Others
Figure 21. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Quality Grade in 2026
Figure 22. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Quality Grade (2021-2026)
Figure 23. Product Picture of PSMA 617 Based Precursors
Figure 24. Product Picture of PSMA I&T Based Precursors
Figure 25. Product Picture of Radiohybrid PSMA Precursors
Figure 26. Product Picture of Bispecific or Multivalent PSMA Precursors
Figure 27. Product Picture of Next Generation PSMA Precursors
Figure 28. Product Picture of Others
Figure 29. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Ligand Platform in 2026
Figure 30. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Ligand Platform (2021-2026)
Figure 31. Product Picture of DOTA Based Chelator Precursors
Figure 32. Product Picture of DOTAGA Based Chelator Precursors
Figure 33. Product Picture of TCMC Based Chelator Precursors
Figure 34. Product Picture of Macropa Based Chelator Precursors
Figure 35. Product Picture of Others
Figure 36. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Chelator System in 2026
Figure 37. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Chelator System (2021-2026)
Figure 38. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumed in argeted Alpha Therapy
Figure 39. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: argeted Alpha Therapy (2021-2026) & (kg)
Figure 40. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumed in Radiolabeling Process Development
Figure 41. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Radiolabeling Process Development (2021-2026) & (kg)
Figure 42. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumed in Clinical Trial Drug Manufacturing
Figure 43. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Clinical Trial Drug Manufacturing (2021-2026) & (kg)
Figure 44. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumed in Quality Control and Reference Use
Figure 45. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Quality Control and Reference Use (2021-2026) & (kg)
Figure 46. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumed in Others
Figure 47. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Others (2021-2026) & (kg)
Figure 48. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Market Share by Application (2025)
Figure 49. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Application in 2025
Figure 50. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Company in 2025 (kg)
Figure 51. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Company in 2025
Figure 52. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Company in 2025 ($ millions)
Figure 53. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Company in 2025
Figure 54. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Geographic Region (2021-2026)
Figure 55. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Geographic Region in 2025
Figure 56. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales 2021-2026 (kg)
Figure 57. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 58. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales 2021-2026 (kg)
Figure 59. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 60. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales 2021-2026 (kg)
Figure 61. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 62. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales 2021-2026 (kg)
Figure 63. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 64. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country in 2025
Figure 65. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Figure 66. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
Figure 67. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 68. United States Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 69. Canada Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 70. Mexico Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 71. Brazil Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 72. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Region in 2025
Figure 73. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Region (2021-2026)
Figure 74. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
Figure 75. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 76. China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 77. Japan Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 78. South Korea Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 79. Southeast Asia Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 80. India Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 81. Australia Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 82. China Taiwan Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 83. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country in 2025
Figure 84. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Figure 85. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
Figure 86. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 87. Germany Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 88. France Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 89. UK Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 90. Italy Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 91. Russia Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 92. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country (2021-2026)
Figure 93. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
Figure 94. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 95. Egypt Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 96. South Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 97. Israel Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 98. Turkey Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 99. GCC Countries Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 100. Manufacturing Cost Structure Analysis of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals in 2026
Figure 101. Manufacturing Process Analysis of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Figure 102. Industry Chain Structure of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Figure 103. Channels of Distribution
Figure 104. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Forecast by Region (2027-2032)
Figure 105. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share Forecast by Region (2027-2032)
Figure 106. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share Forecast by Form (2027-2032)
Figure 107. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share Forecast by Form (2027-2032)
Figure 108. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share Forecast by Application (2027-2032)
Figure 109. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Figure 2. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Growth Rate 2021-2032 (kg)
Figure 7. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country/Region (2025)
Figure 10. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Lyophilized Precursor Powder
Figure 12. Product Picture of Solution Form Precursor
Figure 13. Product Picture of Others
Figure 14. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form in 2026
Figure 15. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Form (2021-2026)
Figure 16. Product Picture of Research Grade
Figure 17. Product Picture of Analytical Grade
Figure 18. Product Picture of Clinical Grade
Figure 19. Product Picture of GMP Grade
Figure 20. Product Picture of Others
Figure 21. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Quality Grade in 2026
Figure 22. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Quality Grade (2021-2026)
Figure 23. Product Picture of PSMA 617 Based Precursors
Figure 24. Product Picture of PSMA I&T Based Precursors
Figure 25. Product Picture of Radiohybrid PSMA Precursors
Figure 26. Product Picture of Bispecific or Multivalent PSMA Precursors
Figure 27. Product Picture of Next Generation PSMA Precursors
Figure 28. Product Picture of Others
Figure 29. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Ligand Platform in 2026
Figure 30. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Ligand Platform (2021-2026)
Figure 31. Product Picture of DOTA Based Chelator Precursors
Figure 32. Product Picture of DOTAGA Based Chelator Precursors
Figure 33. Product Picture of TCMC Based Chelator Precursors
Figure 34. Product Picture of Macropa Based Chelator Precursors
Figure 35. Product Picture of Others
Figure 36. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Chelator System in 2026
Figure 37. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Chelator System (2021-2026)
Figure 38. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumed in argeted Alpha Therapy
Figure 39. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: argeted Alpha Therapy (2021-2026) & (kg)
Figure 40. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumed in Radiolabeling Process Development
Figure 41. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Radiolabeling Process Development (2021-2026) & (kg)
Figure 42. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumed in Clinical Trial Drug Manufacturing
Figure 43. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Clinical Trial Drug Manufacturing (2021-2026) & (kg)
Figure 44. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumed in Quality Control and Reference Use
Figure 45. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Quality Control and Reference Use (2021-2026) & (kg)
Figure 46. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumed in Others
Figure 47. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Others (2021-2026) & (kg)
Figure 48. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sale Market Share by Application (2025)
Figure 49. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Application in 2025
Figure 50. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales by Company in 2025 (kg)
Figure 51. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Company in 2025
Figure 52. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue by Company in 2025 ($ millions)
Figure 53. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Company in 2025
Figure 54. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Geographic Region (2021-2026)
Figure 55. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Geographic Region in 2025
Figure 56. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales 2021-2026 (kg)
Figure 57. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 58. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales 2021-2026 (kg)
Figure 59. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 60. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales 2021-2026 (kg)
Figure 61. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 62. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales 2021-2026 (kg)
Figure 63. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 64. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country in 2025
Figure 65. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Figure 66. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
Figure 67. Americas Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 68. United States Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 69. Canada Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 70. Mexico Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 71. Brazil Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 72. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Region in 2025
Figure 73. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Region (2021-2026)
Figure 74. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
Figure 75. APAC Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 76. China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 77. Japan Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 78. South Korea Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 79. Southeast Asia Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 80. India Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 81. Australia Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 82. China Taiwan Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 83. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country in 2025
Figure 84. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Figure 85. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
Figure 86. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 87. Germany Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 88. France Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 89. UK Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 90. Italy Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 91. Russia Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 92. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Country (2021-2026)
Figure 93. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Form (2021-2026)
Figure 94. Middle East & Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 95. Egypt Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 96. South Africa Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 97. Israel Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 98. Turkey Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 99. GCC Countries Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 100. Manufacturing Cost Structure Analysis of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals in 2026
Figure 101. Manufacturing Process Analysis of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Figure 102. Industry Chain Structure of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals
Figure 103. Channels of Distribution
Figure 104. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Forecast by Region (2027-2032)
Figure 105. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share Forecast by Region (2027-2032)
Figure 106. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share Forecast by Form (2027-2032)
Figure 107. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share Forecast by Form (2027-2032)
Figure 108. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Market Share Forecast by Application (2027-2032)
Figure 109. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Revenue Market Share Forecast by Application (2027-2032)
